The 10th Congress of Angiology 03│Jia Zhenhua, Dean of Hebei Institute of Integrated Traditional Chinese and Western Medicine: The choroid theory has made a major breakthrough in the prevention and treatment of cardiovascular diseases
▲Jia Zhenhua, chairman of the Vascular-Choroid Disease Professional Committee of the Chinese Association of Integrative Medicine and director of the Hebei Academy of Integrative Medicine
On April 16, the 10th Angiology Congress of Integrated Traditional and Western Medicine hosted by the Chinese Society of Integrative Medicine was held in Xi’an.
Wu Yiling, an academician of the Chinese Academy of Engineering, served as the honorary chairman of the conference, and Jia Zhenhua, chairman of the Vascular-Choroid Disease Professional Committee, served as the chairman of the conference. Professors Zhang Yun, Chen Xiangmei, and Wu Yiling, academicians of the Chinese Academy of Engineering, and Professor Eric D Peterson of the University of Texas Southwestern Medical Center, and other authoritative experts in traditional Chinese and western medicine at home and abroad gathered at the conference to focus on the original major theory of traditional Chinese medicine—the guidance of the vein theory In-depth academic exchanges on the latest progress and scientific research results in the prevention and treatment of vascular diseases.
The event was held in the form of “online + online”. In addition to the main venue in Xi’an, 1,784 video sub-venues were set up in 28 provinces in China, and tens of thousands of medical experts watched the conference online.
The theory of veins, the theory of camp and health, breaks through the problem of prevention and treatment of single diseases in the cardiovascular event chain
Professor Jia Zhenhua, Chairman of the Vascular-Choroid Disease Professional Committee of the Chinese Association of Integrative Medicine and Director of the Hebei Academy of Integrative Medicine, delivered a speech, saying that from 2005 to 2016, Academician Wu Yiling presided over two consecutive national 973 plan projects, the first systematic construction of traditional Chinese medicine The vein theory forms an original theory guiding the prevention and treatment of vascular diseases. Focusing on the international problems of microvascular disease, experimental research reveals the common mechanism of collateral dredging drugs and microvascular protection in the intervention of major diseases of the heart, brain, intestines and kidneys, and international standard evidence-based research on the four major international problems in the cardiovascular field. Solve the clinical problem of no-reflow in acute myocardial infarction, provide effective new drugs for patients with cardiac insufficiency and premature ventricular beats, fill the gap in the drug treatment of sinus bradycardia with premature ventricular beats, treat both fast and slow, and integrate rhythm, and significantly improve The clinical efficacy of chronic heart failure has had a major international impact, and a major breakthrough has been made in the treatment of microvascular diseases with traditional Chinese medicine, and won the first prize of the only National Science and Technology Progress Award in the field of medicine and health in 2019.
▲Jia Zhenhua made a welcome speech
Jia Zhenhua introduced that in 2017, the national key research and development plan – “the study of the systemic intervention in cardiovascular event chains guided by the theory of veins and health theory” project proposed “curing the root disease and preventing the disease before it” – preventing upstream factors, treating current lesions, and controlling downstream The new point of view of systemic intervention of transmutation reveals the characteristics of pathogenesis transmutation and the law of medication in the systemic intervention of cardiovascular event chains guided by the vein theory, camp and health theory.
Studies have confirmed that Jinlida granule intervenes in metabolic syndrome with abnormal glucose tolerance, reduces the risk of diabetes, and delays the process of arteriosclerosis; Tongxinluo capsule increases the thickness of the fibrous membrane of vulnerable plaques, reduces acute myocardial infarction cardiovascular events, and improves the prognosis. Reduce malignant arrhythmia and the occurrence of chronic heart failure; Shensong Yangxin Capsules can reduce atrial fibrillation after radiofrequency ablation; Qili Qiangxin Capsules can significantly reduce cardiovascular mortality and heart failure rehospitalization rate in patients with heart failure.
Early prevention and early treatment are the key, collateral dredging drugs can inhibit the chain of cardiovascular events
During the keynote report, Professor Jia Zhenhua also brought an academic report titled “Research on Systemic Intervention of Cardiovascular Event Chains Guided by Context Theory, Yingwei Theory”.
▲Professor Jia Zhenhua made an academic report
Professor Jia Zhenhua pointed out that cardiovascular diseases will develop in a chain. Hypertension, hyperlipidemia, and hyperglycemia are high-risk factors recognized around the world. The “three highs” lead to vascular endothelial damage, atherosclerosis, and acute myocardial infarction due to vulnerable plaque rupture. With further aggravation of the disease, heart rhythm after myocardial infarction Arrhythmia, eventually heart failure, and eventually death. The whole chain is causally connected and develops progressively, and sudden cardiovascular events often cause serious consequences. Therefore, it is urgent to suppress the chain of cardiovascular events.
Recently, the national key research and development program “Research on the Systemic Intervention of Cardiovascular Event Chains under the Guidance of Context Theory, Camp and Health Theory” successfully passed the acceptance of the expert group. The project completed 5 evidence-based studies in accordance with international standards, broke through the bottleneck problem of single disease prevention and treatment, and achieved a major breakthrough in the systematic intervention of cardiovascular event chains.
Among them, the team led by Professor Yang Yuejin from the Fuwai Hospital of the Chinese Academy of Medical Sciences completed the “Evidence-Based Study on Myocardial Protection of 3,797 Cases of Tongxinluo Capsules in the Treatment of Acute Myocardial Infarction”, and presented at the latest high-quality scientific trial section of the 2022 American Heart Association Annual Meeting (AHA) ( LBS-HIT3) report test results. The AHA official report stated that “Tongxinluo can improve the clinical prognosis of patients with ST-segment elevation myocardial infarction (STEMI)”; Professor Kenneth W. Mahaffey (Kenneth W. Mahaffey) of Stanford University School of Medicine commented: “Opened the A new era in the treatment of acute myocardial infarction”; Academician Gao Runlin of the Chinese Academy of Engineering commented: “A breakthrough has been made in the field of acute myocardial infarction treatment, which is a milestone in the field of Chinese medicine research.”
In addition, the project also uses modern experimental technology to reveal the curative effect mechanism and scientific connotation of the drug system for dredging collaterals to intervene in the key pathological links of the cardiovascular event chain. Aiming at the international bottleneck problem of a single disease in the cardiovascular event chain, a series of cycles of drug intervention for metabolic syndrome, abnormal glucose tolerance, vulnerable coronary plaque, acute myocardial infarction, recurrence of atrial fibrillation after radiofrequency ablation, and chronic heart failure have been completed. evidence medical research.
The above-mentioned studies have promoted collateral dredging drugs to enter the consensus of multiple authoritative guidelines, and at the same time promoted the construction of national clinical and scientific research platforms, resulting in significant social benefits and providing an important demonstration for the research of integrated traditional Chinese and Western medicine.